UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  December 7, 2012

Medytox Solutions, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

000-54346

54-2156042

(Commission File Number)

(I.R.S. Employer Identification No.)


400 S. Australian Avenue, Suite 800, West Palm Beach, Florida

33401

(Address of Principal Executive Offices)

(Zip Code)


(561) 855-1626

(Registrant’s Telephone Number, Including Area Code)


 

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Section 1 Registrant's Business and Operations

Item 1.01.  Entering into a Material Definitive Agreement

On December 7, 2012, Medytox Diagnostics, Inc. ("Diagnostics"), a wholly-owned subsidiary of Medytox Solutions, Inc. (the "Company"), pursuant to two Stock Purchase Agreements (the "Purchase Agreements"), purchased an aggregate of 50.5% of the outstanding common stock of Biohealth Medical Laboratory, Inc. ("Biohealth") from Balbino Suarez and Luisa G. Suarez, previously the sole owners.  Biohealth is a licensed clinical laboratory and an enrolled Medicare provider.

The purchase price for the shares of common stock was an aggregate of $265,125, consisting of an aggregate payment of $100,000 in cash at closing and the delivery of a $165,125 promissory note by Diagnostics.  The note is guaranteed by the Company.  The Agreements contain customary representations, warranties and covenants of the parties.  Each party agreed to indemnify the other in the event of any breaches of applicable representations and warranties.  The note is due on August 7, 2013.  Three principal payments will be made:  $75,000 payable on February 7, 2013, $75,000 payable on May 7, 2013 and $15,125 payable on August 13, 2013.  The note may be prepaid at any time without premium or penalty.  The note is secured by the shares of common stock purchased from Balbino Suarez.  The note may be accelerated in the event of nonpayment after notice or upon certain bankruptcy events relating to Diagnostics.

In connection with the Company's loan from TCA Global Credit Master Fund, LP, Biohealth will guarantee the loan and pledge substantially all of its assets as security for the loan.

There are no material relationships between the Company, Diagnostics or any of their affiliates or either of Balbino Suarez or Luisa G. Suarez, other than with respect to the Purchase Agreements.

The foregoing is qualified in its entirety by reference to (i) the Stock Purchase Agreement between Luisa G. Suarez and Diagnostics, a copy of which is filed herewith as Exhibit 10.1, (ii) the Stock Purchase Agreement between Balbino Suarez and Diagnostics, a copy of which is filed herewith as Exhibit 10.2, (iii) the promissory note, a copy of which is filed herewith as Exhibit 10.3, and (iv) the guarantee, a copy of which is filed herewith as Exhibit 10.4.

Section 2 – Financial Information

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth above in Item 1.01 is incorporated by reference.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits

(d)  Exhibits



2




Exhibit Number

Description

10.1

Stock Purchase Agreement, dated as of December 7, 2012, between Luisa G. Suarez and Medytox Diagnostics, Inc.

10.2

Stock Purchase Agreement, dated as of December 7, 2012, between Balbino Suarez and Medytox Diagnostics, Inc.

10.3

Secured Promissory Note, dated December 7, 2012, issued by Medytox Diagnostics, Inc. to Balbino Suarez

10.4

Guarantee of Medytox Solutions, Inc., dated December 7, 2012



3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  December 19, 2012

MEDYTOX SOLUTIONS, INC.


/s/ William G. Forhan

William G. Forhan,
CEO and Chairman
(principal executive officer)


 



4


EXHIBIT INDEX

Exhibit Number

Description

10.1

Stock Purchase Agreement, dated as of December 7, 2012, between Luisa G. Suarez and Medytox Diagnostics, Inc.

10.2

Stock Purchase Agreement, dated as of December 7, 2012, between Balbino Suarez and Medytox Diagnostics, Inc.

10.3

Secured Promissory Note, dated December 7, 2012, issued by Medytox Diagnostics, Inc. to Balbino Suarez

10.4

Guarantee of Medytox Solutions, Inc., dated December 7, 2012




STOCK PURCHASE AGREEMENT

BIOHEALTH MEDICAL LABORATORY, INC.


THIS AGREEMENT is made and entered into as of December 7, 2012 (the "Effective Date"), by and between Luisa G. Suarez (the "Seller") and Medytox Diagnostics, Inc., a Florida corporation (the "Buyer" or "Medytox").

R E C I T A L S:

A.

Biohealth Medical Laboratory, Inc. (the "Company") (i) is a Florida corporation in good standing with the Florida Department of State; (ii) is duly licensed as a clinical laboratory with the Florida Agency for Health Care Administration ("AHCA"); and (iii) is an enrolled Medicare provider.

B.

The Seller owns fifty percent (50%) of the issued and outstanding stock interests of the Corporation as evidenced by the following certificate:

Holder

Certificate Number

Number of Shares

Luisa G. Suarez

_______

50

C.

The Seller desires to sell one-half (.50) shares, which comprise one-half percent (.50%) of the outstanding stock interests of the Company (the “Stock”), and the Buyer desires to purchase the same under the terms and conditions set forth herein.  

THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1.

SALE OF STOCK .  Subject to the provisions of this Agreement, the Seller agrees to sell the Stock to the Buyer. In connection therewith, the Seller agrees to deliver duly endorsed certificates or transfer forms representing the Stock to Buyer at Closing, free and clear of all liens, encumbrances. The Seller further agrees to execute such additional documents and take such additional actions as the Buyer deems necessary to perfect the Buyer's title to the Stock, both before and after Closing. In turn, the Buyer agrees to tender payment of the Purchase Price in accordance with this Agreement.

2.

PURCHASE PRICE .  The total Purchase Price (the "Purchase Price") to be paid for the Stock shall be the sum of Two-Thousand Six-Hundred Twenty-Five Dollars ($2,625).  The Purchase Price shall be paid upon execution of this Agreement.

3.

CLOSING . The Closing shall be effective as of December 7, 2012 (the "Closing Date").  



4.

LICENSES; APPROVALS; NOTICES .  Seller agrees to fully cooperate in providing Buyer with all information necessary for completion of the applications as described herein below.

(a)

Post-Closing AHCA and CLIA Notice : Within fifteen (15) days from the date of Closing, Buyer hereby agrees, at Buyer's sole cost and expense, to submit a notice to AHCA (the "AHCA Notice") of the occurrence of the transaction contemplated hereby.  Buyer shall provide a copy of the AHCA Notice to Seller or Seller's counsel within three (3) business days of submission of the same.

(b)

Post-Closing Medicare Application : Within twenty (20) days from the Closing Date, the Corporation shall prepare and submit a CMS Form 855A Change of Information application (the “CMS Application”), which shall reflect ownership, officers, director(s), and authorized official(s) in connection with the contemplated transaction.  Buyer shall provide a copy of the CMS Application to Seller or Seller's counsel within three (3) business days of submission of the same.

(c)

Post-Closing Medicaid Notice . Within twenty (20) days from the Closing Date, Buyer will submit appropriate notifications to the Florida Medicaid Program  (the "Medicaid Notice") which shall reflect ownership, officers, and director(s) in connection with the contemplated transaction.  Buyer shall provide a copy of the Medicaid Notice to Seller or Seller's counsel within three (3) business days of submission of the same.

(d)

Post-Closing Accreditation Notice . Within twenty (20) days from the date of Closing, the Company shall submit a notice to the accrediting organization (the "Accreditation Notice") advising of the occurrence of the contemplated transaction.  Buyer shall provide a copy of the Accreditation Notice to Seller or Seller's counsel within three (3) business days of submission of the same.

(e)

Post-Closing National Provider Identifier Notice . Within twenty (20) days from the date of Closing, the Company shall submit a notice to the National Plan and Provider Enumeration System (NPPES) (the "NPI Notice") advising of the occurrence of the contemplated transaction.   Buyer shall provide a copy of the NPI Notice to Seller or Seller's counsel within three (3) business days of submission of the same.

5.

REPRESENTATIONS AND WARRANTIES OF THE SELLER . The Seller makes the following representations and warranties to the Buyer:

(a)

Recitals . The recitals in the preamble to this Agreement are true and are hereby incorporated in this Agreement as representations of the Seller.

(b)

Title . The Seller has good and marketable title to the Stock, free from all liens, claims, and encumbrances. The Seller has the right, power, and authority to sell all of the Stock pursuant to this Agreement. Delivery of the certificates and/or transfer forms representing the Stock to the Buyer as contemplated by this Agreement will vest unencumbered title to the Stock in the Buyer.



2


(c)

Organization . The Company is a corporation duly organized and validly existing, and its status is active under the laws of the state of Florida.

(d)

Stock . The Stock consist of one-half (.50) shares which comprise one-half percent (.50%) of the outstanding capital stock of any kind of the Company.  Seller owns the Stock free and clear of all liens, security interests, charges, pledges and other restrictions or encumbrances of any kind.

(e)

Authorization .  Seller has the capacity to execute and deliver this Agreement and to perform its obligations hereunder.  This Agreement has been, and each other document, instrument or agreement to be executed and delivered by Seller in connection with the transactions contemplated hereunder will, upon such delivery, be duly executed and delivered by Seller and constitutes, or upon such execution and delivery will be, the valid and legally binding obligation of Seller, enforceable against it in accordance with its terms and conditions.

(f)

No Conflict or Violation .  Neither the execution and delivery of this Agreement, nor the consummation of the transaction contemplated hereby: (i) will result in a violation of or a conflict with any provision of the organizational documents of the Company; (ii) will result in a breach of, a default under, or give any third party the right to modify, terminate or accelerate any obligation under, any term or provision of any contract or agreement to which the Seller or the Company is a party or by which any of their respective assets are bound; or (iii) will result in a violation by Seller or the Company in any material respect of any governmental order.

(g)

Title to Real Property .  The Company does not own any real property.  The Company operates its business from its premises located at 3399 N.W. 72 Avenue, #222, Miami, FL 33122 (the "Premises"), which Premises is leased by the Company.  A true, correct and complete copy of the Premises lease has been made available to Buyer.  Neither the Company nor to Seller's knowledge any other party is in breach or default under such lease.  The Company has not subleased, licensed or otherwise granted any other party the right to use or occupy the Premises or any portion thereof.  The Company has not collaterally assigned the Premises lease or granted any security interest in the Premises.  To the Seller's knowledge, the improvements to the Premises are in good structural condition and free of any material defects.  To the Seller's knowledge there are no encroachments on the Premises or the improvements thereon.  To the Seller's knowledge, the use and occupancy of the Premises and the improvements to the Premises comply in all material respects with applicable laws including, without limitation, zoning regulations, building codes and health care laws.  To the Seller's knowledge, no party other than the Company has any right to use or occupy any part of the Premises.  The Premises has available adequate utilities, including electricity, telephone, water and sewer for the conduct of the Company's business.  To the Seller's knowledge, the Premises has full access for pedestrian and vehicular ingress and egress to and from public roads adjoining all or a part of such property which is adequate for the use of such property.  To the Seller's knowledge, the Premises is not subject to any pending or threatened assessments for public improvements, impact fees or other similar charges nor subject to any pending or threatened condemnation or eminent domain proceedings.  No agreements relating to the Premises have been made by the Company which would impose an obligation to make any



3


contribution or dedication of money or land or to construct, install or maintain any improvements of a public or private nature on or off the Premises.

(h)

Title to Other Property .  The Company has good and marketable title to, or a valid leasehold interest in, the properties and assets used to conduct its business, including the properties and assets shown on the financial statements provided to Buyer, or acquired after the date thereof, in each case free and clear of all liens, encumbrances or charges.  The assets currently owned by the Company or leased by the Company constitute all of the assets necessary to conduct the business of the Company in accordance with past practices as of the date of the financial statements and as of the date hereof, and are located on the premises of the Company.  The buildings, machinery, equipment, and other tangible assets that the Company owns and leases have been maintained in the ordinary course of business consistent with past practices, and are sufficient for operating the business of the Company as presently conducted.  The Company does not own any real property.

(i)

Financial Statements .  The financial statements of the Company as of December 31, 2011, including a balance sheet, a profit and loss statement and a statement of income and cash flows have been provided to Buyer.  The financial statements (including the notes thereto) have been prepared from the books and records of Company, are correct and complete in all material respects, and present fairly the financial condition of the Company, the assets and liabilities of the Company and its results of operations for the applicable periods.  Since December 31, 2011 there has been no change in the financial statements and no fact or circumstance which could result in a material adverse change in the financial statements.

(j)

Taxes .  The Company has filed all required federal, state, and local tax returns and has fully paid all federal, state, and local taxes due.  In the event that Company incurs a tax deficiency related to events that occurred prior to the Closing Date, irrespective of when the same was determined or assessed, the Seller shall be responsible for any such deficiency.

(k)

Litigation and Claims .  There is no litigation, arbitration, or other legal, judicial, administrative, or governmental action currently pending, or to the knowledge of Seller, threatened against the Company.  There are no other pending claims, asserted or unasserted, against the Company. Seller is not aware of any facts that may give rise to any such proceedings, actions, or claims.  

(l)

Compliance with Applicable Laws .  The Company has complied and is in compliance with all applicable federal, state and local laws, regulations or orders.  No written notice has been received by the Seller or the Company during the past six years preceding the date hereof alleging a violation of any federal, state or local law, regulation or order with respect to the Company or its business.  The Company has not made any bribes, kickback payments or other similar payments of cash or other consideration, including payments to customers or clients or employees of customers or clients for purposes of doing business with such persons, in violation of any law, regulation or order.

(m)

Permits and Licenses . The Company holds, and is in compliance with, all permits, licenses, authorizations, bonds, and accreditations required for the conduct of its



4


business and the ownership of its properties used in the business, including, but not limited to, all licenses, permits and accreditations the Company requires to operate a "high complexity" clinical laboratory and to provide urinalysis testing services.  Exhibit "A" sets forth a list of all of such permits, licenses, authorizations and accreditations.  No written notice from a governmental authority has been received by the Company alleging the failure to hold or be in compliance with any of the foregoing. Seller is not aware of any facts that may give rise to any claims of noncompliance relating to said permits, licenses, authorizations and accreditations.

(n)

Compliance with Company Instruments .  The Company has complied with all provisions of its certificate of organization, any operating agreement and resolutions in the operation and conduct of its business.

(o)

Records .  The books and records of the Company are complete and accurate and reflect all transactions of the Company that properly should have been set forth therein.

(p)

Medicare and Medicaid Provider Status .  The Company is the holder of all Medicare and Medicaid provider numbers and authorizations necessary to receive reimbursement for all those services properly reimbursable in the conduct of its business as a clinical laboratory, including, but not limited to, "high complexity" and urinalysis testing, and the status of the same is in good standing.  The Company has timely filed all requisite claims and other reports required to be filed in connection with all State and Federal Medicare and Medicaid programs, as applicable, due on or before the date hereof, all of which are complete and correct.  There are no claims, actions, appeals or overpayments pending before any commission, board or agency, including, without limitation, any intermediary or carrier, the Provider Reimbursement Review Board, the Centers for Medicare and Medicaid Services ("CMS"), the Florida Agency for Health Care Administration, the Florida Department of Health or other authority, with respect to any Federal or State Medicare or Medicaid or other governmental reimbursement program claims filed by Company on or before the date hereof or any disallowances by any commission, board or agency in connection with any audit or review of such claims.  To the best of Seller's knowledge, no validation review, program integrity review, prepayment review, or other investigation related to Company has been conducted by any authority, including without limitation the HHS Office of Inspector General, the U.S. Department of Justice or the Florida Attorney General, in connection with the Medicare, Medicaid, or other governmental reimbursement program, and to the knowledge of Seller, no such reviews or investigations are scheduled, pending or threatened against or affecting the Company or its operations.   To the best of Seller's knowledge, there are no existing survey deficiencies or any pending plan of correction in connection with the Company's business.

(q)

Other Liabilities .  The Company does not have any obligation or liability (whether accrued, absolute, contingent, unliquidated or otherwise, whether or not known to the Seller, whether due or to become due and regardless of when or by whom asserted except as reflected on the financial statements).  To the knowledge of the Seller, there are no facts or circumstances which could give rise to such obligation or liability.

(r)

Transactions with Affiliates .  None of the Company's members, directors, managers, officers or employees nor any of their respective relatives or affiliates is involved in



5


any business arrangement or relationship with the Company (whether written or oral) or has been in the last three years, and none of the Company's members, directors, managers, officers or employees nor any of their respective relatives or affiliates owns any property or right, tangible or intangible, which is used by the Company or has so within the last three years.

(s)

Insurance .  Seller has provided to Buyer a list of all insurance policies (including policies providing property, casualty, liability, and workers' compensation coverage and bond and surety arrangements) maintained by the Company for the benefit of or in connection with the business of the Company.  With respect to each such insurance policy:  (A) with respect to the Company, the policy is legal, binding, enforceable, and in full force and effect in all material respects and will be unaffected by the Closing; (B) neither the Company nor, to the knowledge of the Seller, any other party to the policy is in material breach or default (including with respect to the payment of premiums or the giving of notices), and no event has occurred which, with notice or the lapse of time, would constitute such a material breach or default, or permit termination, modification, or acceleration, under the policy; and (C) the Company has not, and to the knowledge of the Seller no other party to the policy has, repudiated any material provision thereof. All known claims, if any, made against the Company that are covered by insurance have been disclosed to and accepted by the appropriate insurance companies and are being defended by such appropriate insurance companies.

(t)

Employee Benefit Plans; Labor Matters .  The Company does not have any employee benefit plans.  No union has been certified or recognized as the collective bargaining representative of any of such employees or has attempted to engage in negotiations with the Company regarding terms and conditions of employment.  No unfair labor practice charge, work stoppage, picketing or other such activity relating to labor matters has occurred or is pending. No employee of the Company is subject to any non-compete, nondisclosure, confidentiality, employment, consulting or similar agreements relating to, affecting or in conflict with the present or proposed business activities of the Company.  To the knowledge of the Seller, there are no current or threatened attempts (and there has been no current or threatened attempts within the past two (2) years) to organize or establish any labor union to represent any employees of the Company.

(u)

Disclosures . Neither this Agreement (including any exhibit or schedule hereto) nor any other document delivered pursuant to this Agreement to which the Company is a party, nor any report, certificate or instrument furnished to the Buyer in connection with the transactions contemplated in this Agreement, when read together, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained herein or therein, in light of the circumstances under which they were made, not misleading.

(v)

Broker's Fees .  Neither the Seller nor the Company has any liability or obligation to pay any fees, expenses, or commissions to any broker, investment banker, finder or agent with respect to the transactions contemplated by this Agreement.

6.

Representations and Warranties of the Buyer .  The Buyer represents and warrants to the Seller as follows:



6


(a)

Authorization of Transaction .  The Buyer has the legal right and power to execute and deliver this Agreement and to perform its obligations hereunder.  Each of this Agreement and the Note constitutes the valid and legally binding obligation of the Buyer, enforceable against it in accordance with its terms.

(b)

Non-contravention .  Neither the execution and the delivery of this Agreement, nor the consummation of the transactions contemplated hereby, shall (i) violate any applicable law to which the Buyer is subject, or (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify or cancel, or require any notice under any material agreement, contract, lease, license or instrument to which the Buyer is a party or by which it is bound.  The Buyer is not required to give any notice to, make any filing with, or obtain any authorization, consent or approval of any governmental authority or third party in order for the Buyer to consummate the transactions contemplated by this Agreement.

(c)

Purchase for Investment .  The Buyer is acquiring the Interests solely for investment and not as nominee or agent for the benefit of any other person or entity, and the Buyer has no current intention of distributing, reselling or assigning the Interests.

(d)

No Conflict or Violation .  To the Buyer's knowledge, the execution, delivery and performance of this Agreement by the Buyer and the consummation of the transactions contemplated hereby will not:

(a)

violate any order, judgment, injunction, award or decree of any court, arbitrator or governmental or regulatory body against, or binding upon the Buyer;

(b)

violate any statute, law or regulation of any jurisdiction applicable to the Buyer in connection with the transactions contemplated herein; or

(c)

violate or constitute a default under any mortgage, indenture, deed of trust, lease, contract, obligation, agreement, license or instrument to which the Buyer is a party.

(e)

Sophistication .  The Buyer is sophisticated and experienced in financial, business and investment matters, and, as a result, the Buyer is in a position to evaluate the merits and risks of the acquisition of the Interests and the tax consequences of such acquisition.  The Buyer has had the advice and the assistance of professional advisors in connection with evaluating the transactions contemplated by this Agreement.

(f)

Securities Act .  The Buyer understands that the Interests being sold hereby have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and are being sold in reliance on exemptions for private offerings contained in the Securities Act and in reliance on exemptions from the registration requirements of certain state securities laws.  Because the Interests have not been registered under the Securities Act or applicable state securities laws, the Interests may not be re-offered or resold except through a valid and effective registration statement or pursuant to a valid exemption from the registration requirements under the Securities Act and applicable state securities laws.



7


(g)

Authorization .  The Buyer has the capacity to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been, and each other document, instrument or agreement to be executed and delivered by the Buyer in connection with the transactions contemplated hereunder will, upon such delivery, be duly executed and delivered by the Buyer and constitutes, or upon such execution and delivery will be, the valid and legally binding obligation of the Buyer, enforceable against it in accordance with its terms and conditions.

(h)

Brokers' Fees .  The Buyer has no liability or obligation to pay any fees, expenses, or commissions to any broker, investment banker, finder or agent with respect to the transactions contemplated by this Agreement.

7.

COVENANTS OF SELLER . As a material inducement to Buyer to enter into this Agreement, the Seller agrees as follows:

(a)

Non-Competition .  During the period from the Closing Date to the third anniversary thereof (the "Non-Competition Period"), the Seller will not engage or participate, directly or indirectly, as principal, agent, executive, director, proprietor, joint venturer, trustee, employee, employer, consultant, stockholder, partner or in any other capacity whatsoever, in the conduct or management of, or fund, invest in, lend to, own any stock or any other equity or debt investment in, or provide any services of any nature whatsoever to or in respect of (i) any business that is competitive with or in the same line of business as the Company within the Restricted Area, or (ii) any person or entity that is (or was) a customer or client of the Company at any time during the Non-Competition Period or during the two (2) years prior to the date of this Agreement for any business that is competitive with the Company, provided that nothing herein shall prevent the Seller from making, or continuing any existing or future, passive investments in any publicly-traded company.  The “Restricted Area” shall mean Miami-Dade County, Monroe County and Broward County in the state of Florida.

(b)

Non-Solicitation .  During the Non-Competition Period, the Seller will not, for her own benefit or for the benefit of any person or entity other than Buyer or the Company, (i) solicit, or assist any person or entity to solicit, any officer, director, executive or employee of Buyer or any of its affiliates to leave his or her employment, (ii) hire or cause to be hired any person who is then, or who will have been at any point in time during the Non-Competition Period, an officer, a director, an executive or an employee of Buyer or any of its affiliates, or (iii) engage any person who is then, or who will have been at any point in time during the Non-Competition Period, an officer, director, executive or employee of Buyer or any of its affiliates as a partner, contractor, sub-contractor or consultant.

(c)

Customers .  During the Non-Competition Period, the Seller will not (i) solicit, or assist any person or entity other than Buyer and Company to solicit, any person or entity that is an existing or potential client, customer or payor of Buyer or any of its affiliates, or has been a client, customer or payor of any of Seller, Buyer or the Company or any of Buyer’s affiliates during the prior twenty-four (24) months, to provide any services competitive to the Company or the Buyer or any of its affiliates or (ii) interfere with any of the business relationships of Buyer or any of its affiliates.



8


(d)

Markets .  The Seller acknowledges that the above covenants are manifestly reasonable on their face, and the parties expressly agree that such restrictions have been designed to be reasonable and no greater than is required for the protection of Buyer and its affiliates and are a significant element of the consideration hereunder.

(e)

Invalidity .  If the final judgment of a court of competent jurisdiction declares that any term or provision of this Section 7 is invalid or unenforceable, the parties agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration, or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified to cover the maximum duration, scope or area permitted by law.  In addition, in the event of an alleged breach or violation by the Seller of this Section 7, the Non-Competition Period described above shall be tolled with respect to the Seller until such breach or violation has been duly cured.

8.

CONDITIONS TO CLOSE .  Closing shall be subject to all of the following conditions ("Conditions to Close") being satisfied:

(a)

Buyer's Conditions to Close . The obligations of Buyer under this Agreement are subject to the satisfaction, on or prior to Closing, of the following Conditions to Close:

1.

The delivery by the Seller of the certificates representing the Stock, duly endorsed in blank or accompanied by duly executed stock powers;

2.

Seller's representations and warranties contained within paragraph 5 of this Agreement being reaffirmed and true as of the date of Closing; and

3.

The non-occurrence, during the period of time from the Effective Date to the date of Closing of any change, event or condition which has or may have a material adverse effect on the operations or the financial condition of the Company including, but not limited to, (i) material adverse effects resulting from Seller having incurred any obligations or liability affecting the Company, not in the ordinary course of business; (ii) the Company or Seller having mortgaged, pledged, or restricted any of the Company's assets outside of the Company's ordinary course of business, sold or otherwise disposed of any of the Company's assets outside of the Company's ordinary course of business; or (iii) the termination or threatened termination of any of the Company's material contracts, leases or other agreements and/or authorizations which has or may have a material adverse effect on the Company.

 (b)

Seller's Conditions to Close . The obligations of Seller under this Agreement are subject to the satisfaction on or prior to Closing, of the following Conditions to Close:

1.

The payment of the Purchase Price by Buyer to Seller pursuant to paragraph 2 of this Agreement.



9


9.

NOTICES . All notices to be given under this Agreement shall be in writing and sent by registered or certified mail, return receipt requested.

If to the Seller:

Luisa G. Suarez

2392 N.W. 72 Avenue, Suite 222

Miami, FL 33122


If to the Buyer:


Medytox Diagnostics, Inc.

Suite 800

400 S. Australian Avenue

West Palm Beach, Florida 33401

With a copy to:

J. Everett Wilson, Esq.

Akerman Senterfitt

SunTrust International Center – 25th Floor

One S.E. Third Avenue

Miami, Florida 33131-1714


10.

INDEMNIFICATION .  Seller hereby agrees to indemnify and hold the Company and Buyer harmless from any and all liability, loss, or damages, including all costs of defense, litigation, and attorney's fees, resulting from any claims, demands, costs and judgments arising from a breach of any of the representations and warranties contained in Section 5 of this Agreement or from any acts or omissions of Seller or the Company occurring or accruing prior to Closing.  Buyer and Company, jointly and severally, hereby agree to indemnify and hold the Company and Seller harmless from any and all liability, loss or damages, including all costs of defense, litigation, and attorney's fees resulting from any claims, demands, costs and judgments arising from any acts or omissions of Buyer or the Company occurring or accruing after the date of Closing or any breach of Buyer's representations and warranties under this Agreement.  

11.

REPRESENTATIONS AND TRANSACTION FEES .  The parties hereto shall each bear their own legal fees and costs associated with the transactions contemplated hereby.  The parties hereto acknowledge and agree that they have had full opportunity to seek the advice of legal counsel, accountants and any other experts of their choosing and agree that this Agreement shall be construed and interpreted in absolute parity, and shall not be construed or interpreted against any party by reason of such party's preparation of the initial or subsequent draft of this Agreement.

12.

CONFIDENTIALITY .  This Agreement and the terms thereof shall remain confidential and shall not be disclosed to anyone, except counsel or as otherwise required by law or court order, for any purpose whatsoever without the express written consent of the parties hereto.

13.

SURVIVAL .  The provisions of this Agreement shall survive the Closing of the transaction contemplated hereby.   

14.

ATTORNEY'S FEES .  In the event of any legal action to enforce the terms and conditions of this Agreement or related to a breach hereof, the prevailing party shall be entitled



10


to recover all costs of such actions, including attorney's fees and paralegal fees and all other legal expenses and costs at all pre-suit, trial and appellate levels.

15.

SPECIFIC PERFORMANCE .  The Seller and the Buyer acknowledge and agree that the other parties would be damaged irreparably in the event any of the provisions of this Agreement is not performed in accordance with its specific terms or is otherwise breached.  Accordingly, the Seller and Buyer agree that the other parties shall be entitled to an injunction or injunctions to prevent breaches of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any action instituted in any court in the United States or in any state having jurisdiction over the parties and the matter in addition to any other remedy to which they may be entitled pursuant hereto.

16.

ENTIRE AGREEMENT .   The parties acknowledge and represent that this Agreement contains the entire understanding between the parties and that there are no other agreements between them as to the matters described herein.  

17.

ADDITIONAL DOCUMENTS . Seller and Buyer agree to cooperate fully, and execute any and all supplementary documents, and take all additional actions which may be necessary or appropriate to give full force and effect to the basic terms and intent of this Agreement.

18.

GOVERNING LAW .  The parties agree that this Agreement shall be deemed made and entered into in the state of Florida and shall be governed and construed in accordance with the laws of the state of Florida. Venue for any dispute under this Agreement shall lie in Miami-Dade County, Florida.

19.

SEVERABILITY .  Each term and provision of this Agreement constitutes a separate and distinct undertaking, covenant, term and/or provision hereof. In the event that any term or provision of this Agreement shall be determined to be unenforceable, invalid or illegal in any respect, such unenforceability, invalidity or illegality shall not affect any other term or provision of this Agreement, but this Agreement shall be construed as if such unenforceable, invalid or illegal term or provision had never been contained herein. Moreover, if any term or provision of this Agreement shall for any reason be held to be excessively broad as to time, duration, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent permitted under the applicable law as it shall then exist.

20.

COUNTERPARTS .  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.  Execution may be made by facsimile or PDF image of signature as if an original.

21.

LEASEHOLD DEPOSIT .   Buyer and Seller hereby acknowledge that the landlord is currently holding a security deposit on behalf of the Company pursuant to the lease for the Premises. Seller hereby assigns any and all rights to said security deposit to the Buyer and the Company and Seller waives any rights thereto.  



11


IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.

Seller :



/s/ Luisa G. Suarez

Luisa G. Suarez



Buyer :

MEDYTOX DIAGNOSTICS, INC.



/s/Seamus Lagan

Name:

Seamus Lagan

Title:   CEO and President

 






12


STOCK PURCHASE AGREEMENT

BIOHEALTH MEDICAL LABORATORY, INC.

THIS AGREEMENT is made and entered into as of December 7, 2012 (the "Effective Date"), by and between Balbino Suarez (the "Seller") and Medytox Diagnostics, Inc., a Florida corporation (the "Buyer" or "Medytox").

R E C I T A L S:

A.

Biohealth Medical Laboratory, Inc. (the "Company") (i) is a Florida corporation in good standing with the Florida Department of State; (ii) is duly licensed as a clinical laboratory with the Florida Agency for Health Care Administration ("AHCA"); and (iii) is an enrolled Medicare provider.

B.

The Seller owns fifty percent (50%) of the issued and outstanding stock interests of the Corporation as evidenced by the following certificate:

Holder

Certificate Number

Number of Shares

Balbino Suarez

_______

50

C.

The Seller desires to sell fifty (50) shares, which comprise fifty percent (50%) of the outstanding stock interests of the Company (the “Stock”), and the Buyer desires to purchase the same under the terms and conditions set forth herein.  

THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1.

SALE OF STOCK .  Subject to the provisions of this Agreement, the Seller agrees to sell the Stock to the Buyer. In connection therewith, the Seller agrees to deliver duly endorsed certificates or transfer forms representing the Stock to Buyer at Closing, free and clear of all liens, encumbrances. The Seller further agrees to execute such additional documents and take such additional actions as the Buyer deems necessary to perfect the Buyer's title to the Stock, both before and after Closing. In turn, the Buyer agrees to tender payment of the Purchase Price in accordance with this Agreement.

2.

PURCHASE PRICE .  The total Purchase Price (the "Purchase Price") to be paid for the Stock shall be the sum of Two-Hundred Sixty-Two Thousand Five-Hundred Dollars ($262,500).  The Purchase Price shall be paid as follows:

(a)

Ninety-Seven Thousand Three-Hundred Seventy-Five Dollars ($97,375) Dollars upon execution of this Agreement;

(b)

The remaining balance of the Purchase Price, in the amount of One-Hundred Sixty-Five Thousand One-Hundred Twenty-Five Dollars ($165,125), pursuant to the terms of a Secured Promissory Note.





3.

CLOSING . The Closing shall be effective as of December 7, 2012 (the "Closing Date").  

4.

LICENSES; APPROVALS; NOTICES .  Seller agrees to fully cooperate in providing Buyer with all information necessary for completion of the applications as described herein below.

(a)

Post-Closing AHCA and CLIA Notice : Within fifteen (15) days from the date of Closing, Buyer hereby agrees, at Buyer's sole cost and expense, to submit a notice to AHCA (the "AHCA Notice") of the occurrence of the transaction contemplated hereby.  Buyer shall provide a copy of the AHCA Notice to Seller or Seller's counsel within three (3) business days of submission of the same.

(b)

Post-Closing Medicare Application : Within twenty (20) days from the Closing Date, the Corporation shall prepare and submit a CMS Form 855A Change of Information application (the “CMS Application”), which shall reflect ownership, officers, director(s), and authorized official(s) in connection with the contemplated transaction.  Buyer shall provide a copy of the CMS Application to Seller or Seller's counsel within three (3) business days of submission of the same.

(c)

Post-Closing Medicaid Notice . Within twenty (20) days from the Closing Date, Buyer will submit appropriate notifications to the Florida Medicaid Program  (the "Medicaid Notice") which shall reflect ownership, officers, and director(s) in connection with the contemplated transaction.  Buyer shall provide a copy of the Medicaid Notice to Seller or Seller's counsel within three (3) business days of submission of the same.

(d)

Post-Closing Accreditation Notice . Within twenty (20) days from the date of Closing, the Company shall submit a notice to the accrediting organization (the "Accreditation Notice") advising of the occurrence of the contemplated transaction.  Buyer shall provide a copy of the Accreditation Notice to Seller or Seller's counsel within three (3) business days of submission of the same.

(e)

Post-Closing National Provider Identifier Notice . Within twenty (20) days from the date of Closing, the Company shall submit a notice to the National Plan and Provider Enumeration System (NPPES) (the "NPI Notice") advising of the occurrence of the contemplated transaction.   Buyer shall provide a copy of the NPI Notice to Seller or Seller's counsel within three (3) business days of submission of the same.

5.

REPRESENTATIONS AND WARRANTIES OF THE SELLER . The Seller makes the following representations and warranties to the Buyer:

(a)

Recitals . The recitals in the preamble to this Agreement are true and are hereby incorporated in this Agreement as representations of the Seller.

(b)

Title . The Seller has good and marketable title to the Stock, free from all liens, claims, and encumbrances. The Seller has the right, power, and authority to sell all of the Stock pursuant to this Agreement. Delivery of the certificates and/or transfer forms



2


representing the Stock to the Buyer as contemplated by this Agreement will vest unencumbered title to the Stock in the Buyer.

(c)

Organization . The Company is a corporation duly organized and validly existing, and its status is active under the laws of the state of Florida.

(d)

Stock . The Stock consist of fifty (50) shares which comprise fifty percent (50%) of the outstanding capital stock of any kind of the Company.  Seller owns the Stock free and clear of all liens, security interests, charges, pledges and other restrictions or encumbrances of any kind.

(e)

Authorization .  Seller has the capacity to execute and deliver this Agreement and to perform its obligations hereunder.  This Agreement has been, and each other document, instrument or agreement to be executed and delivered by Seller in connection with the transactions contemplated hereunder will, upon such delivery, be duly executed and delivered by Seller and constitutes, or upon such execution and delivery will be, the valid and legally binding obligation of Seller, enforceable against it in accordance with its terms and conditions.

(f)

No Conflict or Violation .  Neither the execution and delivery of this Agreement, nor the consummation of the transaction contemplated hereby: (i) will result in a violation of or a conflict with any provision of the organizational documents of the Company; (ii) will result in a breach of, a default under, or give any third party the right to modify, terminate or accelerate any obligation under, any term or provision of any contract or agreement to which the Seller or the Company is a party or by which any of their respective assets are bound; or (iii) will result in a violation by Seller or the Company in any material respect of any governmental order.

(g)

Title to Real Property .  The Company does not own any real property.  The Company operates its business from its premises located at 3399 N.W. 72 Avenue, #222, Miami, FL 33122 (the "Premises"), which Premises is leased by the Company.  A true, correct and complete copy of the Premises lease has been made available to Buyer.  Neither the Company nor to Seller's knowledge any other party is in breach or default under such lease.  The Company has not subleased, licensed or otherwise granted any other party the right to use or occupy the Premises or any portion thereof.  The Company has not collaterally assigned the Premises lease or granted any security interest in the Premises.  To the Seller's knowledge, the improvements to the Premises are in good structural condition and free of any material defects.  To the Seller's knowledge there are no encroachments on the Premises or the improvements thereon.  To the Seller's knowledge, the use and occupancy of the Premises and the improvements to the Premises comply in all material respects with applicable laws including, without limitation, zoning regulations, building codes and health care laws.  To the Seller's knowledge, no party other than the Company has any right to use or occupy any part of the Premises.  The Premises has available adequate utilities, including electricity, telephone, water and sewer for the conduct of the Company's business.  To the Seller's knowledge, the Premises has full access for pedestrian and vehicular ingress and egress to and from public roads adjoining all or a part of such property which is adequate for the use of such property.  To the Seller's knowledge, the Premises is not subject to any pending or threatened assessments for



3


public improvements, impact fees or other similar charges nor subject to any pending or threatened condemnation or eminent domain proceedings.  No agreements relating to the Premises have been made by the Company which would impose an obligation to make any contribution or dedication of money or land or to construct, install or maintain any improvements of a public or private nature on or off the Premises.

(h)

Title to Other Property .  The Company has good and marketable title to, or a valid leasehold interest in, the properties and assets used to conduct its business, including the properties and assets shown on the financial statements provided to Buyer, or acquired after the date thereof, in each case free and clear of all liens, encumbrances or charges.  The assets currently owned by the Company or leased by the Company constitute all of the assets necessary to conduct the business of the Company in accordance with past practices as of the date of the financial statements and as of the date hereof, and are located on the premises of the Company.  The buildings, machinery, equipment, and other tangible assets that the Company owns and leases have been maintained in the ordinary course of business consistent with past practices, and are sufficient for operating the business of the Company as presently conducted.  The Company does not own any real property.

(i)

Financial Statements .  The financial statements of the Company as of December 31, 2011, including a balance sheet, a profit and loss statement and a statement of income and cash flows have been provided to Buyer.  The financial statements (including the notes thereto) have been prepared from the books and records of Company, are correct and complete in all material respects, and present fairly the financial condition of the Company, the assets and liabilities of the Company and its results of operations for the applicable periods.  Since December 31, 2011 there has been no change in the financial statements and no fact or circumstance which could result in a material adverse change in the financial statements.

(j)

Taxes .  The Company has filed all required federal, state, and local tax returns and has fully paid all federal, state, and local taxes due.  In the event that Company incurs a tax deficiency related to events that occurred prior to the Closing Date, irrespective of when the same was determined or assessed, the Seller shall be responsible for any such deficiency.

(k)

Litigation and Claims .  There is no litigation, arbitration, or other legal, judicial, administrative, or governmental action currently pending, or to the knowledge of Seller, threatened against the Company.  There are no other pending claims, asserted or unasserted, against the Company. Seller is not aware of any facts that may give rise to any such proceedings, actions, or claims.  

(l)

Compliance with Applicable Laws .  The Company has complied and is in compliance with all applicable federal, state and local laws, regulations or orders.  No written notice has been received by the Seller or the Company during the past six years preceding the date hereof alleging a violation of any federal, state or local law, regulation or order with respect to the Company or its business.  The Company has not made any bribes, kickback payments or other similar payments of cash or other consideration, including payments to customers or clients or employees of customers or clients for purposes of doing business with such persons, in violation of any law, regulation or order.



4


(m)

Permits and Licenses . The Company holds, and is in compliance with, all permits, licenses, authorizations, bonds, and accreditations required for the conduct of its business and the ownership of its properties used in the business, including, but not limited to, all licenses, permits and accreditations the Company requires to operate a "high complexity" clinical laboratory and to provide urinalysis testing services.  Exhibit "A" sets forth a list of all of such permits, licenses, authorizations and accreditations.  No written notice from a governmental authority has been received by the Company alleging the failure to hold or be in compliance with any of the foregoing. Seller is not aware of any facts that may give rise to any claims of noncompliance relating to said permits, licenses, authorizations and accreditations.

(n)

Compliance with Company Instruments .  The Company has complied with all provisions of its certificate of organization, any operating agreement and resolutions in the operation and conduct of its business.

(o)

Records .  The books and records of the Company are complete and accurate and reflect all transactions of the Company that properly should have been set forth therein.

(p)

Medicare and Medicaid Provider Status .  The Company is the holder of all Medicare and Medicaid provider numbers and authorizations necessary to receive reimbursement for all those services properly reimbursable in the conduct of its business as a clinical laboratory, including, but not limited to, "high complexity" and urinalysis testing, and the status of the same is in good standing.  The Company has timely filed all requisite claims and other reports required to be filed in connection with all State and Federal Medicare and Medicaid programs, as applicable, due on or before the date hereof, all of which are complete and correct.  There are no claims, actions, appeals or overpayments pending before any commission, board or agency, including, without limitation, any intermediary or carrier, the Provider Reimbursement Review Board, the Centers for Medicare and Medicaid Services ("CMS"), the Florida Agency for Health Care Administration, the Florida Department of Health or other authority, with respect to any Federal or State Medicare or Medicaid or other governmental reimbursement program claims filed by Company on or before the date hereof or any disallowances by any commission, board or agency in connection with any audit or review of such claims.  To the best of Seller's knowledge, no validation review, program integrity review, prepayment review, or other investigation related to Company has been conducted by any authority, including without limitation the HHS Office of Inspector General, the U.S. Department of Justice or the Florida Attorney General, in connection with the Medicare, Medicaid, or other governmental reimbursement program, and to the knowledge of Seller, no such reviews or investigations are scheduled, pending or threatened against or affecting the Company or its operations.   To the best of Seller's knowledge, there are no existing survey deficiencies or any pending plan of correction in connection with the Company's business.

(q)

Other Liabilities .  The Company does not have any obligation or liability (whether accrued, absolute, contingent, unliquidated or otherwise, whether or not known to the Seller, whether due or to become due and regardless of when or by whom asserted except as reflected on the financial statements).  To the knowledge of the Seller, there are no facts or circumstances which could give rise to such obligation or liability.



5


(r)

Transactions with Affiliates .  None of the Company's members, directors, managers, officers or employees nor any of their respective relatives or affiliates is involved in any business arrangement or relationship with the Company (whether written or oral) or has been in the last three years, and none of the Company's members, directors, managers, officers or employees nor any of their respective relatives or affiliates owns any property or right, tangible or intangible, which is used by the Company or has so within the last three years.

(s)

Insurance .  Seller has provided to Buyer a list of all insurance policies (including policies providing property, casualty, liability, and workers' compensation coverage and bond and surety arrangements) maintained by the Company for the benefit of or in connection with the business of the Company.  With respect to each such insurance policy:  (A) with respect to the Company, the policy is legal, binding, enforceable, and in full force and effect in all material respects and will be unaffected by the Closing; (B) neither the Company nor, to the knowledge of the Seller, any other party to the policy is in material breach or default (including with respect to the payment of premiums or the giving of notices), and no event has occurred which, with notice or the lapse of time, would constitute such a material breach or default, or permit termination, modification, or acceleration, under the policy; and (C) the Company has not, and to the knowledge of the Seller no other party to the policy has, repudiated any material provision thereof. All known claims, if any, made against the Company that are covered by insurance have been disclosed to and accepted by the appropriate insurance companies and are being defended by such appropriate insurance companies.

(t)

Employee Benefit Plans; Labor Matters .  The Company does not have any employee benefit plans.  No union has been certified or recognized as the collective bargaining representative of any of such employees or has attempted to engage in negotiations with the Company regarding terms and conditions of employment.  No unfair labor practice charge, work stoppage, picketing or other such activity relating to labor matters has occurred or is pending. No employee of the Company is subject to any non-compete, nondisclosure, confidentiality, employment, consulting or similar agreements relating to, affecting or in conflict with the present or proposed business activities of the Company.  To the knowledge of the Seller, there are no current or threatened attempts (and there has been no current or threatened attempts within the past two (2) years) to organize or establish any labor union to represent any employees of the Company.

(u)

Disclosures . Neither this Agreement (including any exhibit or schedule hereto) nor any other document delivered pursuant to this Agreement to which the Company is a party, nor any report, certificate or instrument furnished to the Buyer in connection with the transactions contemplated in this Agreement, when read together, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained herein or therein, in light of the circumstances under which they were made, not misleading.

(v)

Broker's Fees .  Neither the Seller nor the Company has any liability or obligation to pay any fees, expenses, or commissions to any broker, investment banker, finder or agent with respect to the transactions contemplated by this Agreement.



6


6.

Representations and Warranties of the Buyer .  The Buyer represents and warrants to the Seller as follows:

(a)

Authorization of Transaction .  The Buyer has the legal right and power to execute and deliver this Agreement and to perform its obligations hereunder.  Each of this Agreement and the Note constitutes the valid and legally binding obligation of the Buyer, enforceable against it in accordance with its terms.

(b)

Non-contravention .  Neither the execution and the delivery of this Agreement, nor the consummation of the transactions contemplated hereby, shall (i) violate any applicable law to which the Buyer is subject, or (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify or cancel, or require any notice under any material agreement, contract, lease, license or instrument to which the Buyer is a party or by which it is bound.  The Buyer is not required to give any notice to, make any filing with, or obtain any authorization, consent or approval of any governmental authority or third party in order for the Buyer to consummate the transactions contemplated by this Agreement.

(c)

Purchase for Investment .  The Buyer is acquiring the Interests solely for investment and not as nominee or agent for the benefit of any other person or entity, and the Buyer has no current intention of distributing, reselling or assigning the Interests.

(d)

No Conflict or Violation .  To the Buyer's knowledge, the execution, delivery and performance of this Agreement by the Buyer and the consummation of the transactions contemplated hereby will not:

(a)

violate any order, judgment, injunction, award or decree of any court, arbitrator or governmental or regulatory body against, or binding upon the Buyer;

(b)

violate any statute, law or regulation of any jurisdiction applicable to the Buyer in connection with the transactions contemplated herein; or

(c)

violate or constitute a default under any mortgage, indenture, deed of trust, lease, contract, obligation, agreement, license or instrument to which the Buyer is a party.

(e)

Sophistication .  The Buyer is sophisticated and experienced in financial, business and investment matters, and, as a result, the Buyer is in a position to evaluate the merits and risks of the acquisition of the Interests and the tax consequences of such acquisition.  The Buyer has had the advice and the assistance of professional advisors in connection with evaluating the transactions contemplated by this Agreement.

(f)

Securities Act .  The Buyer understands that the Interests being sold hereby have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and are being sold in reliance on exemptions for private offerings contained in the Securities Act and in reliance on exemptions from the registration requirements of certain state securities laws.  Because the Interests have not been registered under the Securities Act or applicable state securities laws, the Interests may not be re-offered



7


or resold except through a valid and effective registration statement or pursuant to a valid exemption from the registration requirements under the Securities Act and applicable state securities laws.

(g)

Authorization .  The Buyer has the capacity to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been, and each other document, instrument or agreement to be executed and delivered by the Buyer in connection with the transactions contemplated hereunder will, upon such delivery, be duly executed and delivered by the Buyer and constitutes, or upon such execution and delivery will be, the valid and legally binding obligation of the Buyer, enforceable against it in accordance with its terms and conditions.

(h)

Brokers' Fees .  The Buyer has no liability or obligation to pay any fees, expenses, or commissions to any broker, investment banker, finder or agent with respect to the transactions contemplated by this Agreement.

7.

COVENANTS OF SELLER . As a material inducement to Buyer to enter into this Agreement, the Seller agrees as follows:

(a)

Non-Competition .  During the period from the Closing Date to the third anniversary thereof (the "Non-Competition Period"), the Seller will not engage or participate, directly or indirectly, as principal, agent, executive, director, proprietor, joint venturer, trustee, employee, employer, consultant, stockholder, partner or in any other capacity whatsoever, in the conduct or management of, or fund, invest in, lend to, own any stock or any other equity or debt investment in, or provide any services of any nature whatsoever to or in respect of (i) any business that is competitive with or in the same line of business as the Company within the Restricted Area, or (ii) any person or entity that is (or was) a customer or client of the Company at any time during the Non-Competition Period or during the two (2) years prior to the date of this Agreement for any business that is competitive with the Company, provided that nothing herein shall prevent the Seller from making, or continuing any existing or future, passive investments in any publicly-traded company.  The “Restricted Area” shall mean Miami-Dade County, Monroe County and Broward County in the state of Florida.

(b)

Non-Solicitation .  During the Non-Competition Period, the Seller will not, for her own benefit or for the benefit of any person or entity other than Buyer or the Company, (i) solicit, or assist any person or entity to solicit, any officer, director, executive or employee of Buyer or any of its affiliates to leave his or her employment, (ii) hire or cause to be hired any person who is then, or who will have been at any point in time during the Non-Competition Period, an officer, a director, an executive or an employee of Buyer or any of its affiliates, or (iii) engage any person who is then, or who will have been at any point in time during the Non-Competition Period, an officer, director, executive or employee of Buyer or any of its affiliates as a partner, contractor, sub-contractor or consultant.

(c)

Customers .  During the Non-Competition Period, the Seller will not (i) solicit, or assist any person or entity other than Buyer and Company to solicit, any person or entity that is an existing or potential client, customer or payor of Buyer or any of its affiliates, or has been a client, customer or payor of any of Seller, Buyer or the Company or any of Buyer’s



8


affiliates during the prior twenty-four (24) months, to provide any services competitive to the Company or the Buyer or any of its affiliates or (ii) interfere with any of the business relationships of Buyer or any of its affiliates.

(d)

Markets .  The Seller acknowledges that the above covenants are manifestly reasonable on their face, and the parties expressly agree that such restrictions have been designed to be reasonable and no greater than is required for the protection of Buyer and its affiliates and are a significant element of the consideration hereunder.

(e)

Invalidity .  If the final judgment of a court of competent jurisdiction declares that any term or provision of this Section 7 is invalid or unenforceable, the parties agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration, or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified to cover the maximum duration, scope or area permitted by law.  In addition, in the event of an alleged breach or violation by the Seller of this Section 7, the Non-Competition Period described above shall be tolled with respect to the Seller until such breach or violation has been duly cured.

8.

CONDITIONS TO CLOSE .  Closing shall be subject to all of the following conditions ("Conditions to Close") being satisfied:

(a)

Buyer's Conditions to Close . The obligations of Buyer under this Agreement are subject to the satisfaction, on or prior to Closing, of the following Conditions to Close:

1.

The delivery by the Seller of the certificates representing the Stock, duly endorsed in blank or accompanied by duly executed stock powers;

2.

Seller's representations and warranties contained within paragraph 5 of this Agreement being reaffirmed and true as of the date of Closing; and

3.

The non-occurrence, during the period of time from the Effective Date to the date of Closing of any change, event or condition which has or may have a material adverse effect on the operations or the financial condition of the Company including, but not limited to, (i) material adverse effects resulting from Seller having incurred any obligations or liability affecting the Company, not in the ordinary course of business; (ii) the Company or Seller having mortgaged, pledged, or restricted any of the Company's assets outside of the Company's ordinary course of business, sold or otherwise disposed of any of the Company's assets outside of the Company's ordinary course of business; or (iii) the termination or threatened termination of any of the Company's material contracts, leases or other agreements and/or authorizations which has or may have a material adverse effect on the Company.

 (b)

Seller's Conditions to Close . The obligations of Seller under this Agreement are subject to the satisfaction on or prior to Closing, of the following Conditions to Close:



9


1.

The payment of the Purchase Price by Buyer to Seller pursuant to paragraph 2 of this Agreement.

9.

NOTICES . All notices to be given under this Agreement shall be in writing and sent by registered or certified mail, return receipt requested.

If to the Seller:

Balbino Suarez

2392 N.W. 72 Avenue, Suite 222

Miami, FL 33122


If to the Buyer:


Medytox Diagnostics, Inc.

Suite 800

400 S. Australian Avenue

West Palm Beach, Florida 33401

With a copy to:

J. Everett Wilson, Esq.

Akerman Senterfitt

SunTrust International Center – 25th Floor

One S.E. Third Avenue

Miami, Florida 33131-1714


10.

INDEMNIFICATION .  Seller hereby agrees to indemnify and hold the Company and Buyer harmless from any and all liability, loss, or damages, including all costs of defense, litigation, and attorney's fees, resulting from any claims, demands, costs and judgments arising from a breach of any of the representations and warranties contained in Section 5 of this Agreement or from any acts or omissions of Seller or the Company occurring or accruing prior to Closing.  Buyer and Company, jointly and severally, hereby agree to indemnify and hold the Company and Seller harmless from any and all liability, loss or damages, including all costs of defense, litigation, and attorney's fees resulting from any claims, demands, costs and judgments arising from any acts or omissions of Buyer or the Company occurring or accruing after the date of Closing or any breach of Buyer's representations and warranties under this Agreement.  

11.

REPRESENTATIONS AND TRANSACTION FEES .  The parties hereto shall each bear their own legal fees and costs associated with the transactions contemplated hereby.  The parties hereto acknowledge and agree that they have had full opportunity to seek the advice of legal counsel, accountants and any other experts of their choosing and agree that this Agreement shall be construed and interpreted in absolute parity, and shall not be construed or interpreted against any party by reason of such party's preparation of the initial or subsequent draft of this Agreement.

12.

CONFIDENTIALITY .  This Agreement and the terms thereof shall remain confidential and shall not be disclosed to anyone, except counsel or as otherwise required by law or court order, for any purpose whatsoever without the express written consent of the parties hereto.

13.

SURVIVAL .  The provisions of this Agreement shall survive the Closing of the transaction contemplated hereby.   



10


14.

ATTORNEY'S FEES .  In the event of any legal action to enforce the terms and conditions of this Agreement or related to a breach hereof, the prevailing party shall be entitled to recover all costs of such actions, including attorney's fees and paralegal fees and all other legal expenses and costs at all pre-suit, trial and appellate levels.

15.

SPECIFIC PERFORMANCE .  The Seller and the Buyer acknowledge and agree that the other parties would be damaged irreparably in the event any of the provisions of this Agreement is not performed in accordance with its specific terms or is otherwise breached.  Accordingly, the Seller and Buyer agree that the other parties shall be entitled to an injunction or injunctions to prevent breaches of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any action instituted in any court in the United States or in any state having jurisdiction over the parties and the matter in addition to any other remedy to which they may be entitled pursuant hereto.

16.

ENTIRE AGREEMENT .   The parties acknowledge and represent that this Agreement contains the entire understanding between the parties and that there are no other agreements between them as to the matters described herein.  

17.

ADDITIONAL DOCUMENTS . Seller and Buyer agree to cooperate fully, and execute any and all supplementary documents, and take all additional actions which may be necessary or appropriate to give full force and effect to the basic terms and intent of this Agreement.

18.

GOVERNING LAW .  The parties agree that this Agreement shall be deemed made and entered into in the state of Florida and shall be governed and construed in accordance with the laws of the state of Florida. Venue for any dispute under this Agreement shall lie in Miami-Dade County, Florida.

19.

SEVERABILITY .  Each term and provision of this Agreement constitutes a separate and distinct undertaking, covenant, term and/or provision hereof. In the event that any term or provision of this Agreement shall be determined to be unenforceable, invalid or illegal in any respect, such unenforceability, invalidity or illegality shall not affect any other term or provision of this Agreement, but this Agreement shall be construed as if such unenforceable, invalid or illegal term or provision had never been contained herein. Moreover, if any term or provision of this Agreement shall for any reason be held to be excessively broad as to time, duration, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent permitted under the applicable law as it shall then exist.

20.

COUNTERPARTS .  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.  Execution may be made by facsimile or PDF image of signature as if an original.

21.

LEASEHOLD DEPOSIT .   Buyer and Seller hereby acknowledge that the landlord is currently holding a security deposit on behalf of the Company pursuant to the lease for the Premises. Seller hereby assigns any and all rights to said security deposit to the Buyer and the Company and Seller waives any rights thereto.  



11



IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.

Seller :


/s/ Balbino Suarez

Balbino Suarez



Buyer :

MEDYTOX DIAGNOSTICS, INC.



/s/ Seamus Lagan

Name:

Seamus Lagan

Title:

CEO and President






12


SECURED PROMISSORY NOTE

$165,125

December 7, 2012

FOR VALUE RECEIVED, the undersigned, MEDYTOX DIAGNOSTICS, INC ., a Florida corporation (the “ Borrower ”), hereby promises to pay to the order of BALBINO SUAREZ (the “ Holder ”), the principal amount of One-Hundred Sixty-Two Thousand One-Hundred Twenty-Five Dollars ($162,125) as provided hereunder.

Section 1.

Interest .

A.

Generally .  The Borrower promises to pay interest (“ Interest ”) on the outstanding principal amount of this Note at the rate of 0% per annum (the “ Interest Rate ”).  Interest on this Note shall accrue from the date hereof through and until repayment of the principal amount of this Note and payment of all Interest in full and shall be computed on the basis of a 360-day year of twelve 30-day months.  

B.

Default Rate of Interest .  Notwithstanding the foregoing provisions of this Section 1, but subject to applicable law, any overdue principal of this Note shall bear interest, payable on demand in immediately available funds, for each day from the date payment thereof was due to the date of actual payment, at a rate equal to the sum of the Interest Rate and an additional 2.00% per annum.  

C.

No Usurious Interest .  In the event that any interest rate(s) provided for in this Section 1 shall be determined to be unlawful, such interest rate(s) shall be computed at the highest rate permitted by applicable law.  Any payment by the Borrower of any interest amount in excess of that permitted by law shall be considered a mistake, with the excess being applied to the principal amount of this Note without prepayment premium or penalty; if no such principal amount is outstanding, such excess shall be returned to the Borrower.

Section 2.

Repayment of Principal Amount .  The principal amount of this Note shall be paid as follows:

(a)

$75,000 shall be due and payable on February 7, 2013; and

(b)

$75,000 shall be due and payable on May 7, 2013; and

(c)

$15,125 shall be due and payable on August 7, 2013 (the Maturity Date ").

All accrued Interest shall be due and payable on the Maturity Date.

Section 3.

Prepayment .  This Note may be prepaid, in whole or in part, at any time and from time to time, without premium or penalty.

Section 4.

Payments .  The payment or prepayment of any amount under this Note shall be payable in lawful money of the United States of America.  Any payment under this Note shall be applied first to accrued interest and second to any principal amount outstanding under this Note.



Section 5.

Security .  As collateral security for the payment of this Note, the Borrower hereby pledges, hypothecates, delivers and grants to the Holder a first lien and security interest in the Interests purchased by the Borrower pursuant to the Stock Purchase Agreement, dated as of December 7, 2012, between the Borrower and the Holder.  Upon an Event of Default (as hereinafter defined) the Holder may exercise all rights and remedies as may be available under law (including, without limitation, the Uniform Commercial Code).

Section 6.

Events of Default .  The occurrence (whether such occurrence shall be voluntary or involuntary or come about or be effected by operation of law or otherwise) and continuation for any reason whatsoever of any of the following events shall constitute an “ Event of Default ”:

(a)

the Borrower fails to make payment of any principal on this Note when the same shall become due and payable within 30 days after Holder's written notice to Borrower giving notice of such non-payment;

(b)

the Borrower fails to make payment of any Interest on this Note provided for hereunder when the same shall become due and payable within 30 days after Holder's written notice to Borrower giving notice of such non-payment; or

(c)

the Borrower shall (i) discontinue its business in its entirety, (ii) undergo an event of dissolution, (iii) fail to keep in full force and effect its existence as a corporation, (iv) apply for or consent to the appointment of a receiver, trustee, custodian or liquidator of it or any of its property, (v) admit in writing its inability to pay its debts as they mature, (vi) make a general assignment for the benefit of creditors, (vii) be adjudicated a bankrupt or insolvent or be the subject of an order for relief under Title 11 of the United States Code or (viii) file a voluntary petition in bankruptcy, or an answer seeking reorganization or an arrangement with creditors or to take advantage of any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute, or an answer admitting the material allegations of a petition filed against it in any proceeding under any such law or corporate action shall be taken for the purpose of effecting any of the foregoing.

Section 7.

Rights upon Event of Default .  If an Event of Default described in Section 6 has occurred, the Holder, at its option, may declare the aggregate principal amount of this Note, together with all accrued and unpaid interest thereon, immediately due and payable (except in the case of an Event of Default under paragraph (c) of Section 6, in which event the aggregate principal amount of this Note, together with all accrued and unpaid interest thereon, shall automatically become due and payable).

Section 8.

Transferability .  Holder shall not be entitled to assign, transfer, hypothecate, pledge or otherwise convey all or any part of this Note.



2


Section 9.

Miscellaneous .   

A.

Unconditional Obligation; Waivers .  The obligations of the Borrower to make the payments provided for in this Note are absolute and unconditional and not subject to any defense, set-off, counterclaim, rescission, recoupment or adjustment whatsoever.  Except as provided herein, the Borrower hereby waives presentment and demand for payment, notice of non-payment, notice of dishonor, protest, notice of protest, bringing of suit and diligence in taking any action to collect any amount called for under this Note.  No waiver of any provision of this Note made by agreement of the Holder and any other person shall constitute a waiver of any other terms hereof, or otherwise release or discharge the liability of the Borrower under this Note.  No failure to exercise and no delay in exercising, on the part of the Holder, any right, power or privilege under this Note shall operate as a waiver thereof nor shall partial exercise of any right, power or privilege.  The rights and remedies herein provided are cumulative and are not exclusive of any rights or remedies provided by law.

B.

Notices and Addresses .  Any notice, demand, request, waiver, or other communication under this Note shall be in writing and shall be deemed to have been duly given on the date of service, if personally served or sent by facsimile; on the business day after notice is delivered to a courier or mailed by express mail, if sent by courier delivery service or express mail for next day delivery; and on the third day after mailing, if mailed to the party to whom notice is to be given, by first class mail, registered, return receipt requested, postage prepaid and addressed as follows:

To Borrower:

Medytox Diagnostics, Inc.

400 S. Australian Avenue, Suite 800

West Palm Beach, Florida 33401

With a copy to:

J. Everett Wilson

Akerman Senterfitt

SunTrust International Center

One S.E. Third Avenue, 25 th Floor

Miami, Florida 33131


To Holder:

Balbino Suarez

2392 N.W. 72 Avenue, Suite 222

Miami, FL 33122


C.

Severability; Binding Effect .  Any provision of this Note which is invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Note or affecting the validity or unenforceability of any of the terms and provisions of this Note in any other jurisdiction.  This Note shall be binding upon and inure to the benefit of the parties hereto.  Neither this Note nor any rights or obligations hereunder may be assigned by the Borrower or the Holder.



3


D.

Governing Law .  This Note and any dispute, disagreement, or issue of construction or interpretation arising hereunder whether relating to its execution, its validity, the obligations provided therein or performance shall be governed and interpreted according to the internal laws of the state of Florida, without giving effect to the principles of conflicts of laws thereof.  EACH PARTY HEREBY IRREVOCABLY CONSENTS TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT SITTING IN MIAMI-DADE COUNTY, FLORIDA IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS NOTE, AS WELL AS TO THE JURISDICTION OF ALL COURTS TO WHICH AN APPEAL MAY BE TAKEN FROM SUCH COURTS.

E.

Amendment .  This Note can be amended, supplemented or changed, and any provision hereof can be waived, only by written instrument making specific reference to this Note signed by the Borrower and the Holder

F.

Section Headings .  Section headings herein have been inserted for reference only and shall not be deemed to limit or otherwise affect, in any matter, or be deemed to interpret in whole or in part any of the terms or provisions of this Note.

IN WITNESS WHEREOF , this Note has been executed and delivered as of the date specified above.

MEDYTOX DIAGNOSTICS, INC.

  

/s/ Seamus Lagan      

Name:  Seamus Lagan

Title:

CEO and President



4


GUARANTEE

West Palm Beach, Florida

     7 th December, 2012


In order to induce BALBINO SUAREZ (hereinafter referred to as Holder) to make such advances and extensions of credit, directly or indirectly, to MEDYTOX DIAGNOSTICS, INC. , a Florida corporation (hereinafter referred to as Borrower), and for other valuable consideration, the receipt of which is hereby duly acknowledged, the undersigned (hereinafter referred to as Guarantor) hereby guarantees to the Holder the prompt and unconditional payment of any and every obligation or liability of Borrower to Holder, pursuant to that certain Secured Promissory Note (hereinafter referred to as the Note) in the principal  amount of $165,125.00 made by Borrower in favor of Holder and dated 7 th December, 2012, a copy being attached hereto.


In the event of default under the Note, Guarantor hereby agrees to pay Holder any and all expenses of collection of obligations hereby guaranteed including, but not limited to, court costs and reasonable attorney's fees, including appellate review.


This Guarantee shall also be binding upon the successors and assigns of the Guarantor.


This Guarantee shall for all purposes be governed by the law of the State of Florida.


IN WITNESS WHEREOF, the undersigned has executed and delivered this Guarantee on the date first above written.



MEDYTOX SOLUTIONS, INC.,

a Nevada corporation



By: /s/ William Forhan